Filing summary
Entity mismatch: The supplied filing is Calyxt, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, not a Cibus, Inc. filing. The summary below reflects the filing text provided.
Business context and reporting period
Calyxt is an early-stage agricultural biotechnology company developing gene-edited crops and plant-based products. Its first commercial products, high-oleic soybean oil and meal, began generating sales in early 2019. The company reported results for the year ended December 31, 2019, with quarterly data including Q4 2019. Cellectis owned 68.9% of Calyxt at year-end.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $7.296 million | $0.236 million |
| Cost of goods sold | $9.280 million | — |
| Gross profit (loss) | $(1.984) million | $0.236 million |
| Operating expenses | $37.689 million | $28.351 million |
| Net loss | $(39.612) million | $(27.897) million |
| Basic and diluted loss per share | $(1.21) | $(0.91) |
| Net cash used in operating activities | $(31.951) million | $(20.252) million |
Q4 2019 revenue was $3.764 million, cost of goods sold was $5.415 million, gross loss was $1.651 million, operating expenses were $10.314 million, and net loss was $12.165 million, or $0.37 per share. Q4 2018 revenue was $2,000 and net loss was $8.468 million.
2019 revenue comprised $1.685 million from soybean oil, $5.604 million from soybean meal, and $7,000 from technology licensing. Adjusted EBITDA, a non-GAAP measure, was a loss of $29.840 million, versus a loss of $18.856 million in 2018. Management reported adjusted gross loss of $4.464 million, versus GAAP gross loss of $1.984 million; the adjustment includes prior-period grain costs and an inventory valuation reserve.
At December 31, 2019, cash and cash equivalents were $58.610 million and restricted cash was $1.428 million, for total cash, cash equivalents and restricted cash of $60.038 million. Current liabilities were $7.196 million. Financing lease obligations totaled approximately $18.6 million on the balance sheet, including current and non-current portions. Total assets were $88.098 million and stockholders’ equity was $62.508 million.
Capital expenditures were $2.969 million in 2019. Contractual obligations totaled $81.357 million, including $50.896 million of forward grain and seed purchase commitments and $29.970 million of financing lease payments. The filing states cash resources were expected to fund operations into mid-2021; this is a forward-looking estimate, not a guarantee.
Material changes versus prior periods
- Revenue rose by $7.060 million year over year, principally from commercial soybean oil and meal sales. The company sold all 2019 soybean meal production, generating $5.6 million of revenue.
- Gross margin turned negative as commercial costs exceeded sales at this early stage. The 2019 cost of goods sold includes an $869,000 inventory reserve; 2018 included $3.3 million of grain costs in R&D rather than cost of goods sold, limiting period comparability.
- Net loss increased by $11.715 million. Higher personnel and stock-based compensation costs, increased commercial and supply-chain spending, and negative product margins were key contributors.
- Operating cash use increased by $11.699 million, with higher inventory and receivables after commercialization contributing to working-capital use. Cash and cash equivalents declined from $93.794 million to $58.610 million.
- The company expanded its development funnel from six candidates at December 31, 2018 to 15 products or candidates at December 31, 2019, including one commercial product.
Outlook, risks and unusual items
- Management expected continued operating losses for several years and anticipated needing additional capital to fund longer-term plans. New equity financing could dilute existing shareholders; debt could add fixed payments and restrictions.
- The company reported a 2020 soybean acreage goal of 100,000 contracted acres and said it had exceeded that goal by March 1, 2020. It planned five new seed varieties for the 2020 planting season and expected to continue expanding acreage.
- Management expected at least six product-candidate launches through 2024, including hemp in 2020, alfalfa in 2021 through a collaboration, and high-fiber wheat as early as 2022. These are targets and depend on development, field trials, and regulatory processes.
- A significant portion of high-fiber wheat field-trial plants was damaged by improper aerial chemical applications by unaffiliated parties in early 2020. Calyxt was assessing effects on timing and expected to harvest the remaining crop in spring 2020.
- Key risks include commercialization and scaling costs, demand and price uncertainty, crop and weather exposure, reliance on third-party growers and processors, evolving gene-editing regulation, intellectual-property dependence on Cellectis and the University of Minnesota, and Cellectis’ control and approval rights.
- The company’s commodity-price sensitivity analysis estimated that a 10% increase in futures prices would reduce financial condition by $880,000, while a 10% decrease would increase it by $727,000, based on positions at year-end.
- No material pending legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor expressed an unqualified opinion on the financial statements.
Important facts for investors to verify
- Confirm the correct issuer: the supplied document identifies Calyxt, Inc. (NASDAQ: CLXT), not Cibus, Inc.
- Review product-level sales, realized margins, the inventory reserve, and the differing treatment of grain costs across periods.
- Track cash burn, working-capital needs, financing lease payments, and the $50.9 million of forward purchase commitments against the stated mid-2021 runway.
- Check whether acreage expansion and new seed varieties translate into profitable sales, and whether the high-fiber wheat field damage affects the development schedule.
- Assess potential dilution and governance implications of Cellectis’ majority ownership and contractual control rights.